Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

The Greater Manchester Cancer Alliance

- PMLiVE

Union calls on AstraZeneca to reconsider Alderley Park plans

Unite says move to Cambridge will take years to deliver value

- PMLiVE

AstraZeneca sales hit by Seroquel generics

End of patent exclusivity for antipsychotic among key factors dragging down revenues

- PMLiVE

AstraZeneca supports NHS medication passport app

Backs NIHR-NHS initiative under joint working agreement

- PMLiVE

AstraZeneca signs $200m deal with Bind for cancer drug

Follows deals with Amgen and Pfizer for Bind involving its Accurin nanotechnology

- PMLiVE

AstraZeneca signs cancer biomarkers discovery deal

Partners with UK firm on personalised oncology drug research

- PMLiVE

AZ boosts cardiovascular pipeline with US biotech acquisition

Its MedImmune biologics arm buys AlphaCore Pharma

- PMLiVE

AstraZeneca hit by US Pulmicort patent ruling

Federal court says patent for inhaled steroid drug is invalid

- PMLiVE

NICE: Pfizer’s lung cancer drug Xalkori too expensive for NHS

Pharma company says NICE's data demands need to take ethics into account

- PMLiVE

AstraZeneca settles with generic rivals in Crestor patent challenge

Blocks competition in US until May 2016

- PMLiVE

Additional 2,300 jobs to go at AstraZeneca

Soriot sets out strategy to return to growth

- PMLiVE

AstraZeneca cuts 1,600 jobs in overhaul of global operations

US and UK affected as Soriot pushes ahead with R&D restructuring

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links